CommentChimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?
References (10)
- et al.
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphoblastic leukaemia: a systematic review and meta-analysis
Lancet Haematol
(2020) - et al.
Molecular detection of minimal residual disease precedes morphological relapse and could be used to identify relapse in pediatric and young adult B-cell acute lymphoblastic leukemia patients treated with tisagenlecleucel
Blood
(2018) - et al.
Exploring the dilemma of allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy: to transplant or not?
Biol Blood Marrow Transplant
(2020) - et al.
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
Biol Blood Marrow Transplant
(2019) - et al.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
N Engl J Med
(2013)
There are more references available in the full text version of this article.
Cited by (3)
Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma
2023, Journal of Nuclear MedicineResearch progress of chimeric antigen receptor T cells therapy in hematological malignancies
2021, Chinese Journal of Microbiology and Immunology (China)
© 2020 Elsevier Ltd. All rights reserved.